Best Life Sciences Companies in Belfast, United Kingdom
The 34 best Life Sciences companies in Belfast, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sisaf.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Belfast
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sisaf Provider of drug delivery nano silicon-based drug delivery systems | $33M | 71 mo ago | Series B | 18 18 → 17 (-6%) | Suzanne Siebert Founder & CEO | WordPressMySQLPHP+20 | 95 patents Silicon-based drug delivery carriers and therapeutic formulation technologies | — |
| 2 | B-Secur Platform offering security and authentication solutions | $18M | 39 mo ago | Series B | 70 70 → 37 (-47%) | Alan Foreman Co-Founder & CEO | WordPressMySQLPHP+32 | 36 patents Wearable biometric signal acquisition and health monitoring devices for humans and animals | — |
| 3 | Neurovalens Developer of non-invasive neurostimulation products | $18M | 14 mo ago | Series A | 22 22 → 29 (+32%) | Anthony Rober Wilcox Executive Director | WordPressApple iCloud MailGoogle Workspace+29 | 18 patents Non‑invasive vestibular nerve stimulation devices for anxiety, sleep, and post‑COVID therapy | — |
| 4 | Re-Vana Therapeutics Developer of drug delivery platform forophthalmic diseases | $17M | 46 mo ago | Series A | 1 | Michael O’Rourke CEO | — | 27 patents Biodegradable ocular drug delivery systems and coated eye implants | — |
| 5 | Cumulus Neuro AI and cloud-based brain physiology analysis tool for clinical trials 62Growth top 20%Funding top 30%News top 33%Moat top 39% All 7 signals ▾Growthtop 20% Fundingtop 30% Newstop 33% Moattop 39% Talentbottom 49% Marketbottom 47% Globalbottom 39% Growth: Headcount 21 → 41 (+95%) across vintages · Fresh capital in last 24 mo Funding: Raised $15.2M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $15M | 15 mo ago | Series A | 41 41 → 35 (-15%) | Brian Murphy Co-Founder & Chief Scientific Officer | — | — | — |
| 6 | CV6 Therapeutics Developer of combination therapies for the treatment of cancer | $6M | 47 mo ago | Series A | 6 | — | WordPressMySQLPHP+23 | 65 patents Hydantoin-based deoxyuridine triphosphate (dUTP)ase inhibitors for oncology therapeutics | — |
| 7 | Axis Three Aesthetic consultation by providing 3D patient simulation | $5M | 208 mo ago | Deadpooled | 11 | Steve Crummey CEO | — | — | — |
| 8 | Causeway Sensors Nano-sized sensing chips for detection of early stage cancer | $5M | 57 mo ago | Seed | 5 | — | — | 20 patents Plasmonic nanostructured optical biosensors for multi-well biomarker detection | — |
| 9 | Overwatch Research Online platform for clinical trial data and workflow management | $4M | 61 mo ago | Acquired | 6 | Paul Wilsdon Co-Founder | — | — | — |
| 10 | Sonrai Analytics Developer of software for data analytics and ingishts | $4M | 13 mo ago | Seed | 16 16 → 31 (+94%) | Darragh Mcart Co-Founder & CEO | WordPressMySQLPHP+27 | — | — |
| 11 | Dia Beta Labs Developer of novel therapeutic peptides for metabolic disease treatment | $4M | 16 mo ago | Seed | — | Nigel Irwin Co-Founder | — | — | — |
| 12 | Intelesens Provider of defibrillation and ECG electrodes for vital signs monitoring | $3M | 137 mo ago | Acquired | 30 | — | — | 14 patents Non‑invasive biomedical sensing and monitoring devices, especially surface electrodes and oximetry | — |
| 13 | ProAxsis Developer of diagnostic test for the detection of respiratory conditions | $2M | 15 mo ago | Acquired | 12 12 → 7 (-42%) | David Ribeiro CEO | — | — | — |
| 14 | GenoME Diagnostics Developer of an in-vitro diagnostic test for ovarian cancer | $2M | 43 mo ago | Seed | 2 | Shannon Beattie CEO | — | — | — |
| 15 | Modius Health Device for weight loss | $2M | 108 mo ago | Seed | 21 | Jason McKeown Founder & CEO | — | — | — |
| 16 | PathXL Develops web-based workflow solutions for digital pathology | $1M | 167 mo ago | Acquired | 30 | Des Speed ex-CEO | — | 25 patents Digital pathology image analysis: tissue recognition, normalization, and artifact correction | — |
| 17 | 42Genetics Provider of a platform for NGS data analysis | $1M | 67 mo ago | Seed | 2 | — | — | — | — |
| 18 | VascVersa Developer of cell therapies for vascular regeneration | $951K | 50 mo ago | Seed | 3 | Christina Neill Founder & CEO | — | 2 patents Advanced cell culture media formulations and methods for biomanufacturing | — |
| 19 | Biomarx Developer of automated diagnostic systems for molecular testing at point of care 24Funding top 46%Talent bottom 49%Global bottom 33% All 3 signals ▾Fundingtop 46% Talentbottom 49% Globalbottom 33% Funding: Raised $942k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $942K | 9 mo ago | Seed | — | Sean Macfarlane Founder | — | — | — |
| 20 | SignaCor Developer of therapeutics for cardiac diseases | $334K | 7 mo ago | Seed | — | Chris Watson Founder & CEO | — | — | — |
| 21 | Xenobics Diagnostic kits and reagents for food safety application | $207K | 107 mo ago | Deadpooled | — | Brian Green Co-Founder | — | — | — |
| 22 | Autism Biotech Biochemical test for the early diagnosis of autism | $51K | 98 mo ago | Deadpooled | — | Suzanne Saffie-Siebert Co-Founder | — | 6 patents Autism biomarkers for molecular diagnostics and therapeutic monitoring | — |
| 23 | AMPLY Discovery Provider of AI-based infectious disease drug discovery platform | $20K | 8 mo ago | Seed | 2 | Chris Creevey Co-Founder | — | — | — |
Top 12 Life Sciences companies in Belfast
#1
Series A · Belfast, Northern Ireland · founded 2013 · 22 employees$18Mraised▾
Developer of non-invasive neurostimulation products. The company is developing an electronic headset which include Stimu Slim, a small headset-like medical device that targets an area of the brain known to suppress appetite and induces a metabolic shift within the nervous system.
- Aug 2025Series A$8.1M
- Apr 2024Series A$2.7M
- Dec 2021Grant (prize money)$299.4K
- Jul 2020Series A$6.4M
#2
Series A · Belfast, Northern Ireland · founded 2015 · 41 employees$15.2Mraised▾
AI and cloud-based brain physiology analysis tool for clinical trials. It has a cloud-based platform and device that provides a next generation integrated physiological and digital biomarker platform that has the ability to perform assesment tests, analyse results, real-time data collection, and more for drug discovery.
- Jul 2025Series A$4.4M
- May 2021Series A$8.3M
- Oct 2020Grant (prize money)$237.8K
- Jul 2020Series A$1.4M
#3
Seed · Belfast, Northern Ireland · founded 2018 · 16 employees$3.6Mraised▾
Developer of software for data analytics and insights. The platform is offering AI and ML-based applications which enables users to filter and analyze data sets in real-time to provide results, predictions, or insights based on the analysis for precision medicine. It offers features such as data management, design workflows, data visualization, and many more.
- Sep 2025Seed—
- Nov 2022Seed—
- Jun 2022Seed$2.7M
- Mar 2020Seed$895.5K
#4
Seed · Belfast, Northern Ireland · founded 2025$941.9Kraised▾
Developer of automated diagnostic systems for molecular testing at point of care. The company provides a system that streamlines the diagnostic workflow. It offers a platform combining single-use cartridges with screen-printed electrodes. The system aims to decentralise diagnostic services and expand patient access to testing.
- Jan 2026Grant (prize money)—
- Jan 2026Seed$941.9K
#5
Seed · Belfast, Northern Ireland · founded 2022$3.5Mraised▾
Developer of novel therapeutic peptides for metabolic disease treatment. The company focused on developing novel therapeutic agents for metabolic diseases, particularly targeting the progressive decline of pancreatic beta-cell health in diabetes and obesity. They emphasize peptide analogues that are enzyme resistant, receptor selective, and highly soluble for better formulation. It aims for treatments that offer more sustainable, quality weight loss and better management of disease progression compared to current options.
- Jun 2025Seed$2M
- Jan 2025Grant (prize money)—
- Jan 2025Seed$1.5M
- Oct 2024Grant (prize money)$32.9K
#6
Acquired · Belfast, Northern Ireland · founded 2013 · 12 employees$2.2Mraised▾
Developer of diagnostic test for the detection of respiratory conditions. The company has developed ProteaseTags (active neutrophil elastase immunoassay), which have the capacity to rapidly and selectively bind active proteases. It quantifies the activity of a single protease species within a complex biological sample. They offer services including clinical research services, biomarkers, academic supports, etc.
- Jul 2025Seed$298.6K
- Apr 2024Seed$2.2M
- Feb 2023Conventional Debt$599.8K
- Mar 2015Grant (prize money)$54.3K
#7
Seed · Belfast, Northern Ireland · founded 2024$333.9Kraised▾
Developer of therapeutics for cardiac diseases. It offers a patented low-dose 5-aza therapy that harnesses DNA methylation to address multiple underlying causes of symptomatic hypertrophic cardiomyopathy including established fibrosis a key driver of disease progression.
- Mar 2026Seed$333.9K
#8
Series B · Belfast, Northern Ireland · founded 2014 · 70 employees$18.2Mraised▾
Platform offering security and authentication solutions. It provides tools to help organizations verify identities, manage access, and protect sensitive data. The platform supports workflows related to safeguarding user information and ensuring secure authentication processes.
- Jul 2023Series B—
- Nov 2021Series B$3M
- Sep 2020Series A$1.9M
- May 2020Series A$2.2M
#9
Seed · Belfast, Northern Ireland · founded 2021 · 2 employees$20Kraised▾
Provider of AI-based infectious disease drug discovery platform. It offers a machine learning-based platform for the digital biological biome, high-volume peptide, and protein extraction technology for drug discovery of human and animal AMR molecules.
- Feb 2026Seed—
- May 2025Seed$1.8M
- Feb 2024Grant (prize money)$1.8M
- Sep 2023Seed$20K
#10
Series A · Belfast, Northern Ireland · founded 2015 · 1 employees$16.8Mraised▾
Developer of drug delivery platform for ophthalmic diseases. The company platform is meant for chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. It offers a flagship product EyeLief, is a photo cross-linked sustained-release biodegradable implant delivering both biologic and small molecule drugs .
- Nov 2022Series A$11.9M
- 2020Seed$2.1M
- Jun 2020Seed$1.2M
- 2017Seed$1.6M
#11
Series B · Belfast, Northern Ireland · founded 2006 · 18 employees$32.6Mraised▾
Provider of drug delivery nano silicon-based drug delivery systems. It develops nano silicon particles for medicines, cosmetics, and nutraceuticals. Its platform uses elemental silicon particles with a honeycomb pore structure that allows controlled drug loading, targeting, and release. It also develops cosmeceuticals or nutraceuticals under the product name.
- Nov 2020Series B$13.2M
- Jul 2019Series A$3.8M
- Aug 2018Series A—
- May 2018Series A$4.3M
#12
Series A · Belfast, Northern Ireland · founded 2012 · 6 employees$5.6Mraised▾
Developer of combination therapies for the treatment of cancer. It offers pipeline candidates which include CV6-168 DNA Uracilation agent that targets the enzyme dUTPase for cancer treatment and CV6-1271 a small molecule therapeutic that control the behaviour of damaging immune cells, alleviate symptoms and improve immune system.
- Nov 2022Grant (prize money)$3.4M
- Nov 2022Series A$5.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Belfast researches in biotechnology
- Queen\'s University Belfast18
- Belfast Health and Social Care Trust1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.